Polivy®

Active substance

Polatuzumab vedotin

Holder

Roche

Status

Closed

Indication

In combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.

Public documents

Approbation

Information for the patient

Informed consent

Last update

17/09/2021

Last updated on 13/02/2024